Predictors of locoregional recurrence after neoadjuvant chemotherapy: Results from combined analysis of national surgical adjuvant breast and bowel project B-18 and B-27

Journal of Clinical Oncology

Volumn 30, Issue 32, 2012, Pages 3960-3966

  Mamounas, Eleftherios P ^a,d   Anderson, Stewart J ^a,b   Dignam, James J ^a,e   Bear, Harry D ^a,f   Julian, Thomas B ^a,c   Geyer, Charles E ^a,g   Taghian, Alphonse ^a,h   Wickerham, D Lawrence ^a,c   Wolmark, Norman ^a,c  

^a NSABP Foundation Inc   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

^c ALLEGHENY GENERAL HOSPITAL   (United States)

^d Aultman Health Foundation   (United States)

^e UNIVERSITY OF CHICAGO   (United States)

^f VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^h MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; TAMOXIFEN;

ADULT; ARTICLE; BREAST CANCER; BREAST TUMOR; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RECURRENCE; CANCER SURGERY; CANCER THERAPY; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MASTECTOMY; MULTIPLE CYCLE TREATMENT; MULTIVARIATE ANALYSIS; PARTIAL MASTECTOMY; PREDICTOR VARIABLE; PRIORITY JOURNAL; SENTINEL LYMPH NODE BIOPSY; TUMOR VOLUME;

EID: 84869450792     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2011.40.8369     Document Type: Article

References (24)

1. Recht A, Gray R, Davidson NE, et al: Locoregional failure 10 years after mastectomy and adjuvant chemotherapy with or without tamoxifen without irradiation: Experience of the Eastern Cooperative Oncology Group. J Clin Oncol 17:1689-1700, 1999
2. Katz A, Strom EA, Buchholz TA, et al: Locoregional recurrence patterns after mastectomy and doxorubicin-based chemotherapy: Implications for postoperative irradiation. J Clin Oncol 18:2817-2827, 2000
3. Wallgren A, Bonetti M, Gelber RD, et al: Risk factors for locoregional recurrence among breast cancer patients: Results from International Breast Cancer Study Group Trials I through VII. J Clin Oncol 21:1205-1213, 2003
4. Taghian A, Jeong JH, Mamounas E, et al: Patterns of locoregional failure in patients with operable breast cancer treated by mastectomy and adjuvant chemotherapy with or without tamoxifen and without radiotherapy: Results from five National Surgical Adjuvant Breast and Bowel Project randomized clinical trials. J Clin Oncol 22:4247-4254, 2004
5. [No authors listed]: Effects of radiotherapy and surgery in early breast cancer: An overview of the randomized trials - Early Breast Cancer Trialists' Collaborative Group. N Engl J Med 333:1444-1455, 1995
6. [No authors listed]: Favourable and unfavourable effects on long-term survival of radiotherapy for early breast cancer: An overview of the randomised trials - Early Breast Cancer Trialists' Collaborative Group. Lancet 355:1757-1770, 2000
7. Overgaard M, Hansen PS, Overgaard J, et al: Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy: Danish Breast Cancer Cooperative Group 82b Trial. N Engl J Med 337:949-955, 1997
8. Ragaz J, Jackson SM, Le N, et al: Adjuvant radiotherapy and chemotherapy in node-positive premenopausal women with breast cancer. N Engl J Med 337:956-962, 1997
9. Overgaard M, Jensen MB, Overgaard J, et al: Postoperative radiotherapy in high-risk postmenopausal breast-cancer patients given adjuvant tamoxifen: Danish Breast Cancer Cooperative Group DBCG 82c randomised trial. Lancet 353:1641-1648, 1999
10. Fisher B, Brown A, Mamounas E, et al: Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: Findings from National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol 15:2483-2493, 1997
11. Fisher B, Bryant J, Wolmark N, et al: Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 16:2672-2685, 1998
12. Wolmark N, Wang J, Mamounas E, et al: Preoperative chemotherapy in patients with operable breast cancer: Nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18. J Natl Cancer Inst Monogr 30:96-102, 2001
13. Rastogi P, Anderson SJ, Bear HD, et al: Preoperative chemotherapy: Updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27. J Clin Oncol 26:778-785, 2008
14. Bear HD, Anderson S, Brown A, et al: The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: Preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol 21:4165-4174, 2003
15. Bear HD, Anderson S, Smith RE, et al: Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol 24:2019-2027, 2006
16. Gray RJ: A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 16:1141-1154, 1988
17. Prentice RL, Kalbfleisch JD, Peterson AV Jr, et al: The analysis of failure times in the presence of competing risks. Biometrics 34:541-554, 1978
18. Fine JP, Gray RJ: A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 94:496-509, 1999
19. Buchholz TA, Tucker SL, Masullo L, et al: Predictors of local-regional recurrence after neoadjuvant chemotherapy and mastectomy without radiation. J Clin Oncol 20:17-23, 2002
20. Freidlin B, Korn EL: Testing treatment effects in the presence of competing risks. Stat Med 24: 1703-1712, 2005
21. Dignam JJ, Zhang Q, Kocherginsky M: The use and interpretation of competing risks regression models. Clin Cancer Res 18:2301-2308, 2012
22. Grambsch PM, Therneau TM: Proportional hazards tests and diagnostics based on weighted residuals. Biometrika 81:515-526, 1994
23. Albain K, Barlow W, O'Malley F, et al: Concurrent (CAFT) versus sequential (CAF-T) chemohormonal therapy (cyclophosphamide, doxorubicin, 5-fluorouracil, tamoxifen) versus T alone for postmenopausal, node-positive estrogen (ER) and/or progesterone (PgR) receptor-positive breast cancer: Mature outcomes and new biologic correlates on phase III intergroup trial 0100 (SWOG-8814). Breast Cancer Res Treat 88, 2004 (suppl 1; abstr 37)
24. Mamounas EP, Bellon J: Local-regional therapy considerations in patients receiving preoperative chemotherapy, in Harris JR, Lippman ME, Morrow M, et al (eds): Diseases of the Breast (ed 4). Philadelphia, PA, Lippincott Williams & Wilkins, 2010, pp 730-761